Jade Biosciences, Inc.

JBIO Nasdaq SEC CIK 1798749
Follow Jade Biosciences Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$35.1M −39.2% vs same quarter last year
EPS, diluted −$0.42 +12.5% vs same quarter last year
Operating cash flow −$28.9M −30.7% vs same quarter last year
Operating income −$39.6M −44.7% vs same quarter last year
Net income by quarter
−$5.4M
−$38.2M
−$32.1M
−$25.2M
−$31.9M
−$40.4M
−$55.8M
−$35.1M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
−$150M−$100M−$50M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$127.4M
FY24−$69.6M
FY23−$75.5M
FY22−$51.5M
FY21−$23M
FY20−$9.6M
FY19-
Free cash flowOperating cash flow minus capital expenditure
−$100M−$75M−$50M−$25M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$94.9M
FY24-
FY23−$56.9M
FY22−$39.3M
FY21−$27.6M
FY20-
FY19-